This Impact Breakfast presents seven scientists looking into Covid-19. The talks will borrow from a wide range of topics, from early to late phase studies, testing to vaccine and social innovation. 

This event will be livestreamed. Please register as attending to gain access to the talks. We encourage you to register as soon as possible on Eventbrite.





08:30-08:40: Introduction by Per Morten Sandset, Vice-Rector The University of Oslo and scientist at Research Institute of Internal Medicine (RIIM) at Oslo University Hospital.


08:40.08:55: TSD: a platform for research and innovation with sensitive data. Leon du Toit, USIT/UiO.


08:55-09:10: DHIS2 for Covid -19 surveillance – local innovation and global response. Kristin Braa, HISP/DHIS2 at Department of Informatics, UiO.

09:10-09:25: The dynamics of The COVID-19 pandemic under external drivers at different stages of the pandemic. Nils Christian Stenseth, Faculty of Mathematics and Natural Sciences, UiO.


09:25-09:40: Spatial modelling of COVID-19 in Norway. Solveig Engebretsen, Norwegian Computing Center and UiO.


09:40-09:55: Covid-19 IgG antibody test. Christian Drevon, UiO & Vitas AS.


09:55-10:10: ​COVID-19: Surveillance of medications safety – capitalizing on Norwegian registry data to answer global question. Hedvig Nordeng, Faculty of Mathematics and Natural Sciences, UiO.


10:10-10:25: Targeted vaccine for COVID-19. Ranveig Bråthen, Oslo University Hospital and UiO. 


10:25: Final words


10:30: Program ends



More about the speakers and their presentations:



Leon du Toit, Section Leader, Research Services, Services for Sensitive Data (TSD). UiO, Center for IT. Since the onset of Covid-19, TSD has hosted, among many others, both, and, both of which are NIPH (FHI) questionnaires, most likely the largest qualititive studies in Norway. TSD was also hand-picked by EC-commission and Elixir to be the host of a EOSC-LIFE system for clinical trial data on covid-19 treatment and patient handling. This talk will provide insight into how the NIPH (FHI) studies were implemented and expose the range of research services offered by TSD.



Hedvig Nordeng, Professor, Head of Pharmacoepidemiology and Drug Safety research group, Dpt. Pharmacy, Faculty of Mathematics and Natural Sciences, UiO will look at how medications impact the course of COVID-19,  how can we determine which medications are safe and effective using real-world data and how to ensure adequate monitoring of adverse drug reactions when the COVID-19 vaccines are rolled out.



Nils Christian Stenseth, Professor, The Faculty of Mathematics and Natural Sciences, UiO will briefly present three interlinked Corona studies to improve our understanding of the spatio-temporal dynamics of COVID-19 pandemic, and thus improve the preparedness against future diseases globally. Specifically reflecting on how our studies can help us develop country-specific control strategies.



Solveig Engebretsen, Research Scientist, Norwegian Computing Center and UiO   will look at how can we utilise modern data sources to inform about the spatial spread of COVID-19 in Norway, and predict the number of new hospitalisations. She will consider the model that the Norwegian Institute of Public Health has been using for situational awareness and forecasting of COVID-19 in Norway. 



Christian Drevon, Professor emeritus at Dept of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, UiO. VITAS  Analytical Services      

With support from the Norwegian Research Council, Vitas has developed and validated an IgG serology test for covid-19 in Dried Blood Spots (DBS). In this talk, Drevon will tell about the Vitas antibody study and the developing of modern fingertip tests. Vitas was stablished in 1994 as a spin-off from UiO. Today they are 23 employees and 35 robots.


Kristin Braa - Professor and Head of HISP/DHIS2 at Department of Informatics, University of Oslo Since mid-March, DHIS2 has been deployed for COVID-19 at a national scale by 36 countries in Africa, Asia, Europe, and the Americas. This includes Norway, where DHIS2 is now being used for case registration and contact tracing in 270 municipalities around the country. The DHIS2 system has been recognized as a global public good and leading digital tool for COVID-19 response.  



Ranveig Bråthen - Researcher at Department of Immunology, Oslo University Hospital and University of Oslo Our research group has developed a novel vaccine platform, a DNA vaccine that target the antigen from a pathogen to antigen presenting cells (APC), the main inducer of the adaptive immune system. We want to use our knowledge in vaccine development against influenza and cancer to make an APC-targeted vaccine against COVID-19 disease.


This event will be livestreamed. Please register as attending to gain access to the talks. We encourage you to register as soon as possible on Eventbrite.
Due to safety restrictions, physical attendance may not be possible for this event.